Structure of Fenebrutinib
CAS No.: 1434048-34-6
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
GDC-0853 is a potent and orally BTK inhibitor.
Synonyms: GDC-0853; RG-7845
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 1434048-34-6 |
Formula : | C37H44N8O4 |
M.W : | 664.80 |
SMILES Code : | O=C1C(N2CCN1C3=NC=CC(C(C=C4NC5=NC=C(N6[C@@H](C)CN(C7COC7)CC6)C=C5)=CN(C)C4=O)=C3CO)=CC8=C2CC(C)(C)C8 |
Synonyms : |
GDC-0853; RG-7845
|
MDL No. : | N/A |
InChI Key : | WNEODWDFDXWOLU-QHCPKHFHSA-N |
Pubchem ID : | 86567195 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
Description |
Fenebrutinib (GDC-0853) is characterized as a strong, selective, orally administrable, and reversible inhibitor of Bruton's tyrosine kinase (Btk), with inhibition constants (Kis) of 0.91 nM for the wild-type Btk and 1.6, 1.3, 12.6, and 3.4 nM for the C481S, C481R, T474I, T474M mutants, respectively. It is identified as a candidate for the study of rheumatoid arthritis and systemic lupus erythematosus[1].
|
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
Platelets | 50 nM | 15 minutes | Inhibition of spontaneous platelet aggregation | PMC8744796 |
Platelets | 0.011 μM | 15 minutes | Inhibition of FcγRIIA-mediated platelet aggregation with an IC50 of 11 nM. | PMC6963242 |
Human iPSC-derived microglia | 0.05 nM to 10 μM | 24 hours | To determine the IC50 of Fenebrutinib on TNF-α release after FcγR activation, the result was 5.1 nM. | PMC11514909 |
Human iPSC-derived microglia | 1 μM | 24 hours | To evaluate the inhibitory effect of Fenebrutinib on TNF-α release after FcγR activation, results showed Fenebrutinib significantly reduced TNF-α release. | PMC11514909 |
Madin-Darby canine kidney cells (MDCK) | 20 µM | 90 minutes | To determine the apparent permeability (Papp) of Fenebrutinib in the presence of varying concentrations of HP-β-CD. Results showed that as the concentration of HP-β-CD increased, the apparent permeability of Fenebrutinib decreased. | PMC7689742 |
JeKo-1 cells | 1.4 nM | 17 hours | Evaluate BTK degradation efficiency, PTD10 demonstrated highly potent BTK degradation in JeKo-1 cells | PMC10332445 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
Beagle dogs | Pentagastrin-pretreated dog model | Oral | 100 mg | Single dose | To evaluate the effect of HP-β-CD on the absorption of Fenebrutinib. Results showed that compared to the control group, the HP-β-CD group had a 9-fold decrease in Cmax, a 7-fold decrease in AUC, prolonged Tmax, and a 6.5-fold increase in fecal recovery of Fenebrutinib. | PMC7689742 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT02983227 | Rheumatoid Arthritis | PHASE2 | COMPLETED | 2019-07-17 | Arizona Arthritis & Rheumatolo... More >>gy Associates, P.C., Glendale, Arizona, 85306, United States|Medvin Clinical Research, Covina, California, 91723, United States|TriWest Research Associates, LLC, El Cajon, California, 92020, United States|Saint Jude Heritage Medical Grp, Fullerton, California, 92835, United States|RASF-Clinical Research Center, Boca Raton, Florida, 33486, United States|Clinical Research of West Florida, Clearwater, Florida, 33765, United States|Medication Management, Greensboro, North Carolina, 27408, United States|Oregon Health & Science Uni, Portland, Oregon, 97239, United States|Metroplex Clinical Research Centre, Dallas, Texas, 75231, United States|Baylor Research Inst., Dallas, Texas, 75246, United States|Accurate Clinical Research, Houston, Texas, 77089, United States|Instituto de Investigaciones Clinicas-Mar del Plata, Buenos Aires, B7600FZN, Argentina|APRILLUS, Buenos Aires, C1194AAO, Argentina|Instituto centenario, Buenos Aires, C1204AAD, Argentina|Centro de Investigacion en Enfermedades Reumaticas CIER, Ciudad Autonoma Buenos Aires, C1055AAF, Argentina|Expertia S.A- Mautalen Salud e Investigación, Ciudad Autonoma Buenos Aires, C1128AAE, Argentina|CCBR - Buenos Aires - AR; AxisMed SRL, Ciudad Autonoma Buenos Aires, C1430CKE, Argentina|ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas, Cordoba, X5000BNB, Argentina|Centro de Investigaciones Medicas Mar Del Plata, Mar del Plata, B7600DHK, Argentina|Instituto de Investigaciones Clinicas, Rosario, S2000CVD, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, 5400, Argentina|Centro Medico Privado de Reumatologia; Reumathology, San Miguel, T4000AXL, Argentina|CIP - Centro Internacional de Pesquisa X; Pesquisa Clinica, Goiania, GO, 74110-120, Brazil|CMiP - Centro Mineiro de Pesquisa*X*, Juiz de Fora, MG, 36010-570, Brazil|Centro de Estudos em Terapias Inovadoras - CETI, Curtiba, PR, 80030-110, Brazil|CCBR Brasil Centro de Pesquisas e Análises Clínicas Ltda., Rio de Janeiro, RJ, 21941-913, Brazil|LMK Servi?os Médicos S/S, Porto Alegre, RS, 90480-000, Brazil|CAEP - Centro Avancado de Estudos e Pesquisas Ltda., Campinas, SP, 13087-567, Brazil|IMA Brasil - Instituto de Medicina Avancada, Sao Paulo, SP, 05437-000, Brazil|MHAT "Eurohospital" - Plovdiv, OOD; Internal Department, Plovdiv, 4002, Bulgaria|UMHAT "Kaspela", EOOD, Plovdiv, 4002, Bulgaria|Medizinski Zentrar-1-Sevlievo EOOD, Sevlievo, 5400, Bulgaria|MHAT "Hadzhi Dimitar", OOD, Sliven, 8800, Bulgaria|Medical Center Excelsior OOD, Sofia, 1000, Bulgaria|NMTH "Tsar Boris III", Sofia, 1233, Bulgaria|DCC "Alexandrovska", EOOD; Clinic of Neurology, Sofia, 1431, Bulgaria|MC "Synexus - Sofia", EOOD, Sofia, 1784, Bulgaria|UMHAT "SofiaMed", OOD; Department of Neurology, Sofia, 1797, Bulgaria|Centro de Investigacion Medico Asistencial S.A.S, Barranquilla, 80020, Colombia|Centro de Investigacion en Reumatologia y Especialdades Medicas SAS. CIREEM, Bogota, 110221, Colombia|Riesgo de Fractura S.A., Bogota, 110221, Colombia|Consultorio Medico en Fundacion el Hospitalito de morelos A.C., Cuernavaca, Morelos, 62170, Mexico|Centro de Investigacion en Reumatologia, Merida, Yucatan, 97070, Mexico|Consultorio Particular del Dr. Miguel Cortes Hernandez, Cuernavaca, 62290, Mexico|Centro de Investigacion de Tratam Innovadores de Sin SC, Culiacan, 80230, Mexico|Centro de Investigacion en Enfermedades Reumaticas y Osteoporosis, Mexicali, 21100, Mexico|Centro de Investigacion Clínica GRAMEL S.C, Mexico, 03720, Mexico|Policlinica Medica de Queretaro S.C., Queretaro, 76000, Mexico|Clinical Research Institute, Tlalnepantla, 54055, Mexico|Unidad de Enfermedades Reumaticas y Cronicodegenerativas, Torreon, 27000, Mexico|NZOZ ZDROWIE Osteo-Medic, Bialystok, 15-351, Poland|Szpital Uniwersytecki; nr 2 im. Dr J. Biziela, Bydgoszcz, 85-168, Poland|Centrum Medyczne Pratia Katowice I, Katowice, 40-081, Poland|CCBR - Lodz - PL, Lodz, 90-368, Poland|ETYKA Osrodek Badan Kliniczynch, Olsztyn, 10-117, Poland|Ai Centrum Medyczne Sp. Z O.O Sp.K., Poznan, 61-113, Poland|Medycyna Kliniczna, Warszawa, 00-660, Poland|Centrum Medyczne AMED, Warszawa, 03-291, Poland|KO-MED Centra Kliniczne Zamosc, Zamosc, 22400, Poland|SBIH of Yaroslavl region " Regional Clinical Hospital "; Therapy, Yaroslavl, Jaroslavl, 150062, Russian Federation|Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova, Moscow, Moskovskaja Oblast, 115522, Russian Federation|SBIH of Moscow "City Clinical Hospital # 1 n. a. N. I. Pirogov", Moscow, Moskovskaja Oblast, 119049, Russian Federation|SPb SBIH "Clinical Rheumatological Hospital # 25", Saint-Petersburg, Sankt Petersburg, 190068, Russian Federation|Sanavita LLC, Sankt-peterburg, Sankt Petersburg, 195257, Russian Federation|LLC Medical Sanitary Unit, Sankt-peterburg, Sankt Petersburg, 196066, Russian Federation|Center of Family Medicine LC, Yekaterinburg, Sankt Petersburg, 620043, Russian Federation|SBHI of Yaroslavl Region Clinical Hospital #3, Yaroslavl, Volgograd, 150051, Russian Federation|SMMIH "Chelyabinsk Regional Clinical Hospital", Chelyabinsk, Voronez, 454076, Russian Federation|SAHI of Kem. "Regional Clinical Hospital for War Veterans", Kemerovo, 650000, Russian Federation|OOO Family Polyclinic, Korolev, Moscow Region, 141060, Russian Federation|Practical Medicine, Moscow, 115404, Russian Federation|Limited Liability Company "Centre of Medical Common Practice", Novosibirsk, 630091, Russian Federation|Ultramed, Omsk, 644024, Russian Federation|SEIHPE Saratov State Medical University n.a. V.I. Razumovskiy, Saratov, 410012, Russian Federation|NIH "Departmental Hospital on Station Smolensk of OJSC "Russian Railways", Smolensk, 214025, Russian Federation|Siberian State Medical University, Tomsk, 634050, Russian Federation|SHI Ulyanovsk Reg Clinical Hospital, Ulyanovsk, 432063, Russian Federation|Territorial Clinical Hospital #2, Vladivostok, 690035, Russian Federation|Institute of Rheumatology, Belgrade, 11000, Serbia|Clinical Center Kragujevac, Kragujevac, 34000, Serbia|Institute of Treatment and Rehabilitation "Niska Banja", Niska Banja, 18205, Serbia|Special hospital for rheumatic diseases Novi Sad, Novi Sad, 21000, Serbia|General Hospital "Dr Laza K. Lazarevic" Sabac, Sabac, 15000, Serbia|MI of Healthcare Kyiv RCH P.L. Shupyk NMA of PGE, Kyiv, Chernihiv Governorate, 01601, Ukraine|CI of Healthcare Kharkiv CCH #8 Dept of Therapy Kharkiv MA of PGE of MOHU, Kharkiv, Kharkiv Governorate, 61176, Ukraine|CI of TRC, Ternopil, Kherson Governorate, 46002, Ukraine|Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU, Ivano-Frankivsk, KIEV Governorate, 76008, Ukraine|SI NSС M.D. Strazhesko Institute of Cardiology of NAMSU, Kyiv, KIEV Governorate, 03680, Ukraine|Medical Center of Revmotsentr LLC, Kyiv, KIEV Governorate, 04070, Ukraine|Medical Center of Limited Liability Company Medical Clinic Blagomed, Kyiv, KIEV Governorate, 1023, Ukraine|Med Center of International Institute of Clinical Trials LLC; Medical Center "OK!Clinic+", Kyiv, KIEV Governorate, 2091, Ukraine|Lviv Regional Clinical Hospital Dept of Rehmuaatology D. Halytskyi Lviv NMU, Lviv, KIEV Governorate, 79010, Ukraine|CH of State Border Service of Ukraine (Military Base 2522); Dept of Therapy, D.Halytskyi Lviv NMU, Lviv, KIEV Governorate, 79014, Ukraine|A.Novak Transcarpathian Regional Clinical Hospital, Uzhgorod, KIEV Governorate, 88018, Ukraine|National Pirogov Memorial Medical University, Vinnytsia, Podolia Governorate, 21018, Ukraine|Railway Transp DCH of HealthCenter Branch of PJSC Ukr Railway Dept of Rheumatology, Dnipro, Tavria Okruha, 49008, Ukraine|City Clinical Hospital #9 Dept of Therapy SI Zaporizhzhia MA of PGE of MoHU, Zaporizhzhia, Tavria Okruha, 69065, Ukraine|CI City Hospital #1, Zaporizhzhia, Tavria Okruha, 69104, Ukraine|CI Lutsk CCH Volyn Regional Center of Cardiovascular Pathology and Thrombolysis, Lutsk, Volhynian Governorate, 43024, Ukraine|GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv, 61039, Ukraine|CNI Consultative and Diagnostic Center of Desnianskyi District of Kyiv, Kyiv, 02232, Ukraine|M.V. Sklifosovsky Poltava RCH Dept of Rheumatology HSEIU UMSA, Poltava, 36011, Ukraine|CI City Hospital #7, Zaporizhzhia, 69118, Ukraine|CI Zaporizhzhia Regional Clinical Hospital of ZRC, Zaporizhzhia, 69600, Ukraine Less << |
NCT03407482 | Lupus Erythematosus, Systemic | PHASE2 | TERMINATED | 2019-11-20 | Valerius Medical Group, Los Al... More >>amitos, California, 90720, United States|RASF-Clinical Research Center, Boca Raton, Florida, 33486, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, 33511, United States|Clinical Research of West Florida, Clearwater, Florida, 33765, United States|Institute of Arthritis Research, Idaho Falls, Idaho, 83404, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, 70809, United States|Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, 27617, United States|Tekton Research Inc, Austin, Texas, 78745, United States|Accurate Clinical Research, Houston, Texas, 77058-3675, United States|Accurate Clinical Research, Houston, Texas, 77089, United States|Arthritis Clinic Of Central Texas, San Marcos, Texas, 78666, United States|APRILLUS, Buenos Aires, C1194AAO, Argentina|Hospital Italiano de La Plata, La Plata, 1900, Argentina|CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica, San Juan, 5400, Argentina|Centro Médico Privado de Reumatología, San Miguel de Tucuman, T4000AXL, Argentina|CIP - Centro Internacional de Pesquisa, Goiania, GO, 74110-120, Brazil|Centro Mineiro de Pesquisa - CMIP, Juiz de Fora, MG, 36036-330, Brazil|Edumed - Educa??o e Saúde SA, Curitiba, PR, 80440-080, Brazil|Centro de Pesquisas em Diabetes - CPD, Porto Alegre, RS, 90035-170, Brazil|Clinica de Neoplasias Litoral, Itajai, SC, 88301-220, Brazil|Faculdade de Medicina do ABC - FMABC, Santo Andre, SP, 09060-650, Brazil|Centro Multidisciplinar de Estudos Clínicos - CEMEC*X*, Santo Andre, SP, 09190-510, Brazil|Centro de Pesquisas Clinicas; CPCLIN, Sao Paulo, SP, 01228-200, Brazil|Hospital Abreu Sodré - AACD, Sao Paulo, SP, 04023-000, Brazil|MHAT Plovdiv, Plovdiv, 4003, Bulgaria|Medical Center "Teodora", EOOD, Ruse, 7000, Bulgaria|Medical Center Excelsior OOD, Sofia, 1000, Bulgaria|UMHAT "Sv. Ivan Rilski", EAD, Sofia, 1431, Bulgaria|MC "Synexus - Sofia", EOOD, Sofia, 1784, Bulgaria|Medical Center "Nov Rehabilitatsionen Tsentar", EOOD, Stara Zagora, 6000, Bulgaria|CTR Estudios SPA, Providencia, 7500571, Chile|Dermacross, Santiago, 66901, Chile|Centro de Estudios Reumatologi, Santiago, 7501126, Chile|Biomedica, Santiago, Chile|Centro Integral de Reumatologia del Caribe SAS CIRCARIBE SAS, Barranquilla, 00000, Colombia|Centro de Investigacion Medico Asistencial S.A.S, Barranquilla, 80020, Colombia|Medicity S.A.S., Bucaramanga, 680003, Colombia|Servimed S.A.S., Bucaramanga, 680003, Colombia|Hospital Pablo Tobon Uribe, Medellin, 050034, Colombia|Konkuk University Medical Center, Seoul, 05030, Korea, Republic of|Centro de Investigacion Alberto Bazzoni S.A. de C.V., Torreon, Coahuila, 27000, Mexico|Unidad de Atencion Medica e Investigacion en Salud S.C., Mérida, Yucatan, 97000, Mexico|Hospital Angeles Lindavista, Mexico, 07760, Mexico|Hospital Universitario de Saltillo, Saltillo, 25000, Mexico|Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosi S.l.p., 78240, Mexico|Fundación Profesor Novoa Santos, A Coruna, LA Coru?a, 15006, Spain|Hospital Universitari Vall d'Hebron, Barcelona, 08035, Spain|Hospital General Universitario Gregorio Mara?on, Madrid, 28007, Spain|Hospital Clinico Universitario Valladolid, Valladolid, 47005, Spain|Hospital Universitario Rio Hortega, Valladolid, 47012, Spain|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 00833, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Guy's Hospital; Louise Coote Lupus Unit, London, SE1 9RT, United Kingdom Less << |
NCT03693625 | Urticaria | PHASE2 | TERMINATED | 2019-10-23 | Clinical Research Center of Al... More >>abama, LLC, Birmingham, Alabama, 35209, United States|Allergy & Asthma Immunology Associates, Scottsdale, Arizona, 85251, United States|Kern Allergy Med Clinic, Inc., Bakersfield, California, 93301, United States|Southern California Research Center, Mission Viejo, California, 92691, United States|Allergy & Asthma Consultants, Redwood City, California, 94063, United States|Integrated Research Group Inc, Riverside, California, 92506, United States|Renstar Medical Research, Ocala, Florida, 34470, United States|Vital Prospects Clinical Research Institute PC - CRN, Tulsa, Oklahoma, 74136, United States|Asthma, Nasal Disease, and Allergy Research Center of New England, East Providence, Rhode Island, 02914, United States|Timber Lane Allergy and Asthma Research, LLC, Burlington, Vermont, 05403, United States Less << |
NCT01991184 | Lymphocytic Leukemia, Chronic,... More >> Diffuse Large B-Cell Lymphoma Less << | PHASE1 | COMPLETED | 2022-03-08 | Stanford Cancer Center, Stanfo... More >>rd, California, 94305-5820, United States|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, 43212, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, 97401-8122, United States|Oregon Health Sciences Uni, Portland, Oregon, 97239, United States|Sarah Cannon Cancer Center - Tennessee Oncology, Pllc, Nashville, Tennessee, 37203, United States|Seattle Cancer Care Alliance, Seattle, Washington, 98109, United States|Princess Alexandra Hospital Woolloongabba; Clinical Hematology and Medical Oncology, Woolloongabba, Queensland, 4102, Australia|Peter MacCallum Cancer Centre; Department of Haematology, Melbourne, Victoria, 3002, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, 6009, Australia Less << |
NCT03596632 | Healthy Participants | PHASE1 | COMPLETED | 2018-08-23 | Covance Clinical Research Unit... More >>, Inc, Madison, Wisconsin, 53704, United States Less << |
Tags: Fenebrutinib | GDC-0853 | GDC0853 | GDC 0853 | Btk | Bruton tyrosine kinase | Btk C481S | Btk C481R | Btk T474I | Btk T474M |Btk inhibitor | 1434048-34-6
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL